Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

Memphasys (ASX: MEM) is attempting something many ASX biotechs promise but few deliver: a clean pivot from scientific validation to commercial execution. The company’s narrative has shifted decisively away from proving the science and towards proving the business model.

As director Marjan Mikel put it bluntly, the shift has been deliberate and recent: “we made [the strategy] very public in around about September, October of last year… to focus solely and wholly on the commercialisation” .

At the centre of the story is the Felix™ system, a sperm separation device that replaces decades-old centrifugation methods. The company positions it as the first meaningful advance in andrology workflows in over 40 years, combining electrophoresis and filtration to produce higher-quality sperm samples in roughly six minutes, versus up to 45 minutes using traditional methods .

That speed is not just a clinical curiosity - it is the economic hook.

The real product: cartridges, not consoles

From a commercial perspective, the real product is not the machine but the consumable cartridge. Each IVF or ICSI cycle requires one cartridge, turning every procedure into a revenue event.

Mikel is explicit about this distinction: “our business model is not selling a device… it’s selling a new sperm separation technique that requires a Felix cartridge to be used every single time” .

This “razor-and-blade” model is well-worn territory in medtech, but Memphasys is only now beginning to prove it works in practice.

The March quarter appears to mark a turning point. Revenue reached roughly $111,000 across multiple regions, including Japan, Europe and the Middle East, representing the first meaningful multi-market contribution .

More telling than the headline number is what sits underneath. As Mikel noted: “we are getting repeat orders from existing clients… which is where our business model is built” .

From trial to workflow adoption

That distinction matters. Early-stage medtech stories often stall at the “trial phase”, where promising technology fails to embed into everyday workflows. Memphasys is arguing that hurdle has been cleared.

Clinics are not just testing Felix; they are incorporating it into standard operating procedures. In Mikel’s words: “we are getting involved in the workflows of these organisations… and that’s really important” .

The company’s commercial strategy has been reset accordingly. Gone is the diffuse R&D focus; in its place is a tightly defined go-to-market approach centred on direct engagement with IVF clinics and carefully selected partners.

Management has explicitly rejected traditional catalogue-style distribution. As Mikel put it: “you just can’t put it on a catalogue and expect it to sell itself” .

Why clinics are buying in

The pitch to clinics is straightforward and commercially grounded. Felix reduces sperm preparation time from around 45 minutes to approximately six minutes, standardises outcomes and improves lab throughput.

In IVF labs, time quite literally is money. Faster processing means more procedures per day, which directly boosts clinic revenue.

Mikel leans heavily on simplicity as the killer feature: “this is how easy it is… press button. That’s it” . He adds that even non-specialists can operate the system: “someone as dumb as me could do this… that’s how easy it is” .

The simplicity is not just anecdotal. As shown in the process diagram on page 12, the workflow is reduced to a handful of steps before activation, reinforcing how easily it integrates into lab routines .

Europe and MENA: where the growth lies

Geographically, Europe and MENA are the primary battlegrounds. Europe alone accounts for around one million IVF cycles annually, and the recently secured CE mark opens that market in full.

The company has already secured contracts in both regions and is seeing repeat demand. Mikel highlighted the significance of this early traction: “we’ve got contracts… and importantly, we are getting repeat orders” .

Japan provides a useful proof-of-concept market with ongoing repeat orders, but it is not the immediate focus. India, pending regulatory approval, represents a near-term expansion opportunity, while Australia and New Zealand are positioned as the next step following TGA approval.

The numbers start to stack up

The economics begin to look compelling when scaled. Management is targeting cartridge pricing of $80 to $150, with cost of goods below $40, implying gross margins above 60% .

Each clinic is expected to generate between $100,000 and $300,000 in annual revenue, depending on procedure volumes.

Mikel frames the model in simple, cumulative terms: “every single client builds on the previous clients… it’s a recurring revenue stream” .

This is where the leverage lies. Each new clinic does not replace revenue - it stacks on top of it.

Scaling brings its own challenges

Of course, early commercialisation is rarely smooth. Revenue remains somewhat lumpy as orders are shipped in batches, and scaling manufacturing to meet demand will require capital.

In fact, demand may already be testing capacity. Mikel was unusually candid on this point: “we are going to have to raise capital… because we’re selling too much Felix” .

That funding, however, is framed as growth capital rather than survival capital, with options ranging from debt to order-backed financing.

A large and growing market backdrop

The broader market backdrop is supportive. Global fertility rates are declining, and assisted reproductive technologies are a growing industry, forecast to expand significantly over the next decade .

Male infertility accounts for a substantial portion of cases, and the lack of innovation in sperm preparation techniques provides a clear opening for disruption.

As Mikel summarised: “there is no shortage of opportunity… every cycle is more revenue for us” .

The inflection point

Memphasys now sits at an inflection point rather than a destination. The technology case appears largely settled; the commercial case is just beginning to take shape.

The key question is whether early signs - repeat orders, multi-market revenue and contracted agreements - translate into sustained, scalable growth.

Mikel’s definition of success is tellingly operational: “broadening the number of clients… and making sure that they are reordering Felix on a regular basis” .

If that plays out, the story shifts from speculative biotech to a medtech platform with annuity-style revenues. If not, it risks joining the long list of promising technologies that never quite made the leap from lab bench to balance sheet.

Imricor Medical Systems has taken another step in its US rollout, lodging its NorthStar Mapping System with the FDA for a pediatric label expansion via the Special 510(k) pathway. For investors, the key point is not just the filing itself, but what it says about the company’s commercial playbook: get NorthStar into receptive hospitals early, build an installed base, and use that foothold to support the broader launch of its full electrophysiology platform in the world’s biggest healthcare market.

A logical follow-up to January’s adult clearance

The move follows NorthStar’s FDA clearance for adult patients in January 2026, so this is not a standing-start regulatory event. Rather, it looks like an extension of a strategy already under way. Imricor is trying to convert regulatory progress into actual hospital adoption, and the pediatric segment appears to be one of the first commercial doors it believes it can push open.

That matters because small medtech companies often win by sequencing their markets carefully. Instead of waiting for broad-based adoption across adult hospitals, Imricor is targeting areas where the product’s value proposition may be especially compelling. In this case, that means children’s hospitals, where reducing radiation exposure is likely to resonate strongly with clinicians and administrators alike.

Why pediatrics could be more than a niche

Imricor says there are more than 250 children’s hospitals in the United States and that it has already received inbound interest from that customer group following the adult clearance. That is an encouraging detail because it suggests demand discovery is already happening without the company having to spend heavily to manufacture it. Hospitals are making the running, or at least picking up the phone.

The pediatric angle also appears commercially attractive for another reason. NorthStar is used in interventional cardiovascular magnetic resonance procedures, and Imricor argues it may improve workflows that are currently performed using standard MRI system interfaces alone. If that proves true in practice, the product is not merely a regulatory novelty but a tool that could make an existing clinical process more usable and more efficient. Investors should always pay attention when a device company can point to workflow improvement, because hospitals do not buy technology simply because it is clever. They buy it when it solves a problem.

Building revenue before the full platform lands

One of the more interesting aspects of the update is that management frames pediatrics as an early commercial channel ahead of broader US adoption of the full EP platform in adult hospitals. In plain English, Imricor is trying to create revenue opportunities and clinical reference sites now, rather than waiting for the whole strategic puzzle to be completed.

That matters because installed base tends to be one of the most valuable currencies in medtech. Once a hospital adopts a system, trains staff and develops familiarity with its use, the odds improve that further products from the same ecosystem can follow. Imricor is effectively trying to seed the market. A handful of pediatric wins could do more than add sales - they could provide proof points, physician advocates and operational learnings for a wider US expansion.

The company also notes it can already sell NorthStar to children’s hospitals that have proactively contacted it. The label expansion, if cleared, would allow it to market proactively into that segment rather than waiting for inbound interest. That is a meaningful distinction. Passive demand is useful; active selling is better.

Timing, momentum and the next watchpoint

Imricor expects clearance in the current quarter. That gives the market a near-term catalyst to watch. The real test, though, will not be the filing or even the clearance alone. Investors will want to see whether regulatory progress converts into orders, placements, and eventually recurring procedure-related revenue.

Chief executive Steve Wedan said the submission was an “exciting and practical step” to accelerate US commercialisation and argued that pediatric centres could become an important adoption channel. He also used the update to underline a broader strategic message: Imricor does not want to be seen solely as an iCMR ablation company, but as a wider interventional MR business.

That broader framing is important. It suggests NorthStar is not just a single-product story, but part of a larger attempt to establish Imricor in MRI-guided interventional cardiology. For shareholders, that is the attraction and the challenge. The attraction is a potentially differentiated platform in a large market. The challenge is that commercial traction still needs to be demonstrated, one hospital at a time.

For now, the pediatric filing looks like a sensible and potentially value-accretive move. It broadens the addressable market, sharpens the company’s US commercial narrative, and gives investors a clearer sense of how Imricor intends to turn regulatory wins into real-world adoption.

Pathkey.AI Limited has taken a meaningful step forward in its commercialisation journey, securing a services agreement with Imunexus Therapeutics Limited valued at up to $100,000.

While the contract size is relatively modest, the importance of the deal lies in what it represents. This is a clear shift from development and validation of the technology to actual revenue generation - a key milestone for any emerging AI company.

The agreement includes an upfront payment component, providing immediate revenue, with additional value tied to milestone-based services. Importantly, it establishes a commercial relationship that has the potential to expand over time.

TrialKey Moves into Real-World Use

At the centre of the engagement is Pathkey’s flagship TrialKey platform, which is being embedded into Imunexus’ clinical development and capital raising workflows.

The platform will be applied across a range of high-value use cases, including clinical trial design optimisation, probability of success analysis and benchmarking against global datasets. It will also support investor communications and broader capital markets positioning.

This breadth of application is significant. It highlights that TrialKey is not a single-purpose tool, but rather a platform that can sit across both scientific and commercial functions within a biotech company. That dual capability has the potential to broaden its addressable market.

A Repeatable Commercial Model Emerging

The structure of the engagement provides further insight into how Pathkey intends to scale.

The services are delivered in phases, starting with a pilot and baseline analytics, before moving into deeper clinical integration and ongoing reporting. This approach enables Pathkey to establish an initial foothold, while creating a pathway to expand its role over time.

This “land and expand” model is well understood in technology businesses and, if executed effectively, can lead to recurring revenue and higher lifetime value per client.

Management has indicated that this engagement is intended to serve as a template for future deals, with the potential to replicate the model across additional biotechnology and pharmaceutical clients.

Why This Matters for Investors

For early-stage technology companies, the key inflection point is always commercial validation.

This agreement demonstrates that Pathkey’s technology is not only functional, but also valued by a third-party customer operating in a real-world setting. It provides early evidence that the platform can integrate into existing workflows and deliver practical utility.

Equally important is the potential for scalability. The clinical development sector is large and increasingly data-driven, with a growing need for tools that improve decision-making, reduce risk and enhance efficiency.

Pathkey’s positioning at the intersection of clinical development and capital markets support could prove to be a differentiator as the company builds out its client base.

Outlook

While the financial contribution from this contract is unlikely to be material in the near term, the strategic importance is clear.

The focus now shifts to execution - converting additional clients, expanding existing relationships and demonstrating a pathway to recurring revenue.

If Pathkey can successfully replicate this model across multiple engagements, it may begin to establish the foundations of a scalable AI-driven business. For investors, this marks an early but important step in that journey.

If ever there were a sector enjoying both a cyclical uplift and a structural re-rating, it’s defence - and increasingly, its Siamese twin, energy security. Argonaut analyst Pia Donovan’s latest sector note (31 March 2026) paints a picture of a world where geopolitics is doing the heavy lifting for order books, with Australian contractors positioned squarely in the slipstream.

At the heart of the thesis is the uncomfortable reality that war - specifically the escalating US-Israel-Iran conflict - has become a powerful economic catalyst. In just four days, some 5,200 munitions were deployed, a statistic that reads less like a battlefield update and more like a procurement forecast. The Pentagon’s mooted US$200 billion supplemental funding request (up from an earlier US$50 billion estimate) underscores how quickly inventories are depleted and replenishment cycles accelerate.

And if that weren’t enough, the Trump administration’s proposed US$1.5 trillion defence budget for FY27 signals a step-change in baseline spending. For Australian investors, the key takeaway is not just the magnitude, but the spillover: allies are being nudged - if not shoved - towards lifting their own defence outlays.

Australia: from reluctant spender to strategic participant

Australia, currently allocating around 2% of GDP to defence, is under increasing pressure to move towards 3.5%. Donovan notes that even the government’s projected rise to 2.33% by 2033 may fall short of expectations, particularly as NATO members target 5% by 2035.

Domestically, the spending trajectory is already formidable. Defence funding is expected to climb from A$59 billion this year to around A$100 billion annually by 2034, with nearly A$350 billion earmarked for capabilities over the decade.

But it’s not just the quantum - it’s the composition. Submarines, shipbuilding, and northern base infrastructure dominate the agenda. The Henderson Defence Precinct alone could absorb A$25 billion over time, while upgrades at HMAS Stirling and Osborne will underpin Australia’s AUKUS ambitions.

For contractors, this is less a pipeline and more a firehose.

Fuel security: the sleeper theme

If defence spending is the headline act, fuel security is the subplot rapidly stealing the show.

The closure of the Strait of Hormuz has exposed Australia’s reliance on imported fuel, prompting renewed urgency around domestic storage. Pre-war estimates of A$3.7-4.8 billion in fuel infrastructure investment now look conservative.

Argonaut highlights Saunders (SND) and Duratec (DUR) as key beneficiaries, given their exposure to fuel storage construction and maintenance. The logic is compelling: building new tanks is slow and capital-intensive, whereas refurbishing existing infrastructure offers a quicker fix - playing directly into Duratec’s wheelhouse.

There’s also a policy kicker. With criticism mounting over low fuel reserves, governments may mandate higher domestic storage levels or redirect supply domestically. Either way, more steel in the ground is required.

Energy crossover: margins meet momentum

The report makes a persuasive case that defence contractors with energy exposure are enjoying a double tailwind.

Duratec’s energy segment, for instance, delivered nearly 77% revenue growth between FY24 and FY25, with margins approaching 30%. Civmec (CVL) is also seeing strong momentum, forecasting FY26 energy revenue of A$110.8 million at a healthy 13.5% EBIT margin.

Even Bhagwan Marine (BWN), not traditionally pigeonholed as an energy play, derives more than half its revenue from oil and gas-linked activity following its Riverside Marine acquisition. Decommissioning - often overlooked - is emerging as a lucrative niche.

In short, energy exposure is no longer a side hustle; it’s a margin enhancer.

Company positioning: ships, steel and services

Among the coverage names, Austal (ASB) stands out for its leverage to US defence spending, with over 70% of revenue tied to its American operations. Expansion at its Mobile shipyard positions it well for major naval programs, while domestically it remains a cornerstone of Australia’s shipbuilding strategy.

Civmec and Duratec earn “key pick” status, thanks to their dual exposure to defence and energy, as well as strong pipelines of contract opportunities. Saunders offers leverage to fuel infrastructure, albeit with execution risks around meeting EBITDA guidance.

Bhagwan Marine, meanwhile, boasts the highest total shareholder return potential (82%), driven by offshore services and decommissioning upside.

Risks: the usual suspects, with a twist

No defence bull case would be complete without caveats. Argonaut flags the perennial risks: delays in government spending, labour shortages, and the possibility of work being insourced by Defence as capabilities grow.

Labour, in particular, looms large. With Defence targeting 69,000 personnel by the early 2030s, competition for skilled workers could constrain project delivery.

Still, there’s a counterbalance. A tight labour market may actually reinforce collaboration between government and industry, ensuring contractors remain integral to execution.

Valuation: steady as she goes

Despite the upbeat outlook, valuation changes are modest. Austal’s price target dips slightly to A$6.60 due to higher capex, while Civmec, Duratec, Saunders and Bhagwan Marine remain unchanged. All retain BUY ratings - a rare display of unanimity.

The underlying message is clear: the story hasn’t changed, but the conviction remains intact.

Final word

Argonaut’s report reads like a sector caught in the crosshairs of global instability - and benefiting accordingly. Defence spending is rising not by choice but by necessity, while fuel security has emerged as an equally pressing concern.

For ASX-listed contractors, this convergence creates a rare alignment of macro tailwinds. Ships need building, tanks need filling, and infrastructure needs upgrading. It’s not quite a golden age - but it’s certainly a busy one.

Amplia Therapeutics has handed investors something small biotechs rarely manage without a raised eyebrow from the market - a data update that looks better after independent review rather than worse. The company says a formal centralised assessment of its ACCENT pancreatic cancer study has lifted the tally of complete responses to five patients, taking the complete response rate to 7.8% across 64 patients treated with 400mg of narmafotinib in combination with gemcitabine and Abraxane. Median overall survival has also come in at 11.1 months, which management says is about two months better than chemotherapy alone, while tolerability remains broadly in line with standard treatment.

For investors, the headline is not merely that the numbers improved. It is that the improvement came from an independent central read using RECIST 1.1 criteria, the standard yardstick for measuring tumour response. That matters because centrally reviewed oncology data generally carry more weight than site investigator assessments. In plain English, the company is now leaning on a tougher referee - and still walking away with a stronger scorecard.

Why complete responses matter so much in pancreatic cancer

Pancreatic cancer is one of oncology’s graveyards for optimism, so complete responses are not just nice-to-have statistics. They are rare enough to make seasoned investors put down their coffee. Amplia compares its 7.8% complete response rate with 0.2% in the historical MPACT trial and 0.3% in the more recent NAPOLI 3 study for gemcitabine and Abraxane alone. Its objective response rate was updated to 35.9%, versus 23% in MPACT and 36.2% in NAPOLI 3.

The complete response figure is particularly eye-catching because it suggests narmafotinib may be doing something more meaningful than simply nudging tumours backwards a touch. A confirmed complete response means scans showed the disappearance of measurable tumours and metastases for at least two months without new lesions appearing. In this disease setting, that is about as close as one gets to a clinical showstopper without breaking out the confetti cannon.

That said, investors should keep both feet on the floor. ACCENT is a Phase 1b/2a, single-arm study, so the comparisons are against historical trials rather than a head-to-head control arm. Cross-trial comparisons can be informative, but they are never perfect because patient populations, trial design and treatment settings can differ. Even so, when a small study starts producing outcomes that sit comfortably beside, or even above, established benchmarks, the market tends to take notice.

Survival data add substance, not just sparkle

The 11.1-month median overall survival figure gives the update more ballast. Amplia notes this exceeds the 8.5 months reported in MPACT for gemcitabine-Abraxane and matches the 11.1 months achieved by NALIRIFOX in NAPOLI 3, the regimen that went on to win US FDA approval. That does not mean narmafotinib is destined for the same regulatory path, but it does place the result in commercially relevant company.

Just as importantly, the company says narmafotinib continues to be well tolerated, with an adverse event profile similar to chemotherapy alone. In oncology, efficacy gets the market excited, but tolerability is what keeps development programmes alive. A drug that adds survival without piling on toxicity has a much better chance of finding a place in the treatment landscape.

The next valuation trigger is credibility with outsiders

Amplia has also been selected to present the trial data at the annual meeting of the American Association of Cancer Research in April. For investors, that is not just a diary note. External presentation at a respected cancer meeting is one of the ways a small biotech moves from telling its own story to having that story interrogated by clinicians, researchers and potential partners.

Chief executive Dr Chris Burns has described the latest results as demonstrating significant clinical benefit and said the complete response rate offers new hope for first-line pancreatic cancer patients. Corporate language always deserves a pinch of salt, but the underlying message is clear enough: Amplia believes narmafotinib now has data strong enough to justify broader scientific scrutiny and, potentially, commercial interest.

What investors should watch from here

The obvious question is whether these results can be converted into the sort of evidence regulators and larger pharmaceutical groups want to see. ACCENT is ongoing, with four patients still on study as of mid-March and one nearing 24 months on trial. More mature data could further strengthen the narrative, but the real prize is a later-stage study that confirms the benefit in a controlled setting.

For now, Amplia has improved the quality of its evidence, not just the gloss on the presentation slides. In a sector where many companies promise the moon and deliver a blurry snapshot, that is a meaningful distinction. The updated ACCENT data do not remove development risk, and pancreatic cancer remains a brutal proving ground. But they do suggest narmafotinib is edging from interesting to genuinely consequential - and that is usually when investors start paying closer attention.